Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

The effectiveness of bleb revision after the glaucoma ExPRESS filtration device implantation

Poster Details

First Author: G. Parkhomenko UKRAINE

Co Author(s):    S. Medvedchuk   T. Petrovska   S. Prysyazhnaya   Y. Gnatenko   I. Chukanov        

Abstract Details


To investigate efficacy of bleb revision depending on the model of the shunt.


'The New Vision' Clinic group, Kyiv, Cherkasy, Khmelnitsky, Ukraine


60 patients with open-angle glaucoma with previous Ex-PRESS shunt surgery and cataract phacoemulsification were divided into 2 groups of 30 persons (30 eyes) each, depending on the model of the implanted device (P-50, P-200).Visual acuity, IOP, number of medications and complications were assessed in 3, 6, 9, 12. 18, 24 and 30 months. Patients with IOP over 21mm Hg on 3 or more medications underwent subsequent bleb revision with mitomycin C, restoration of the shunt passability with viscocanalostomy cannula and suprachoroidal space drainage. Follow-up time after the revision was 21 months.


In group І during the follow-up period IOP elevated over 21mm Hg in 11 eyes, in group II – in 7 eyes. In both groups medications reduced IOP in 6 eyes. In 5 eyes in group І and in 1 eye in group ІІ, where IOP was over 21mm Hg on 3 or more medications, bleb revision was performed. In group I it was successful in 4 eyes, in 1 patient revision was repeated in 6 months. In group II only 1 patient underwent bleb revision after Ex-PRESS shunt surgery. It was successful throughout the follow-up period.


Patients with P-200 model of glaucoma EX–PRESS filtration device showed better IOP control, less need of post-operative medications and subsequent bleb revision. Further research with larger sample size and longer follow-up is needed to confirm these results.

Financial Disclosure:


Back to Poster listing